

Novavax Investor Relations

Deliveries of Novavax' COVID-19 vaccine continue around the world, with doses arriving in Canada on March 29. Health Canada granted authorization for Nuvaxovid™ COVID-19 Vaccine (Recombinant protein, Adjuvanted) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older [last month](#).

Release procedures are underway, as required with all vaccines, and it is anticipated that the vaccine will be available to Canadians in the coming weeks.

For more information on Nuvaxovid, including the Summary of Product Characteristics with Package Leaflet, Prescribing Information and Important Safety Information, adverse event reporting instructions, or to request additional information, please visit the following websites:

- [Health Canada](#)
- Novavax [global authorization website](#)

The brand name Nuvaxovid™ has not yet been authorized for use in the U.S. by the FDA.

<https://ir.novavax.com/Novavax-Statement-on-Arrival-of-its-COVID-19-Vaccine-in-Canada>